2021
Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV
Kennedy AJ, McGinnis KA, Merlin JS, Edelman EJ, Gordon AJ, Korthuis PT, Skanderson M, Williams EC, Wyse J, Oldfield B, Bryant K, Justice A, Fiellin DA, Kraemer KL. Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. Journal Of Substance Use And Addiction Treatment 2021, 132: 108509. PMID: 34130128, PMCID: PMC8628025, DOI: 10.1016/j.jsat.2021.108509.Peer-Reviewed Original ResearchConceptsOpioid use disorderVACS Index 2.0Viral loadMOUD receiptART initiationCD4 countART adherenceUse disordersVeterans Aging Cohort Study (VACS) dataBehavioral treatmentHIV clinical outcomesLog viral loadCD4 cell countAntiretroviral treatment initiationCohort study dataPoor health outcomesPre-post changesHIV outcomesTreatment initiationClinical outcomesMedication treatmentMOUD treatmentPWHHealth outcomesCell count
2018
Machine learning selected smoking-associated DNA methylation signatures that predict HIV prognosis and mortality
Zhang X, Hu Y, Aouizerat BE, Peng G, Marconi VC, Corley MJ, Hulgan T, Bryant KJ, Zhao H, Krystal JH, Justice AC, Xu K. Machine learning selected smoking-associated DNA methylation signatures that predict HIV prognosis and mortality. Clinical Epigenetics 2018, 10: 155. PMID: 30545403, PMCID: PMC6293604, DOI: 10.1186/s13148-018-0591-z.Peer-Reviewed Original ResearchConceptsWhite blood cellsSmoking-associated DNA methylationHIV prognosisInfection-related clinical outcomesBlood cellsSmoking-associated CpGsHIV-positive individualsImmune-related outcomesEpigenome-wide significant CpGsClinical outcomesTobacco smokingVeteran populationSurvival rateDNA methylation indexMortalityFrailtyHIVMethylation indexPrognosisMethylation signaturesDNA methylationOutcomesCell cycleCpGSignificant CpGsPast year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*
Khan MR, McGinnis KA, Grov C, Scheidell JD, Hawks L, Edelman EJ, Fiellin DA, McInnes DK, Braithwaite RS, Justice AC, Wang EA. Past year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*. AIDS Care 2018, 31: 349-356. PMID: 30064277, PMCID: PMC6699634, DOI: 10.1080/09540121.2018.1499861.Peer-Reviewed Original ResearchConceptsHIV-positive MSMSex risk behaviorsViral loadSubstance useDrug useRisk behaviorsNon-injection drug useTransmission riskMultiple sex partnershipsDetectable viral loadHIV viral loadHIV transmission riskInjection drug useNew HIV infectionsHIV-positive menPrior incarcerationHealth care programsHIV infectionClinical outcomesPast yearCare programSociodemographic factorsSocial determinantsRisk determinantsMSM
2016
Religion, Spirituality, and HIV Clinical Outcomes: A Systematic Review of the Literature
Doolittle BR, Justice AC, Fiellin DA. Religion, Spirituality, and HIV Clinical Outcomes: A Systematic Review of the Literature. AIDS And Behavior 2016, 22: 1792-1801. PMID: 28004218, DOI: 10.1007/s10461-016-1651-z.Peer-Reviewed Original ResearchConceptsHIV clinical outcomesClinical outcomesSystematic reviewFurther longitudinal studiesEnglish-language articlesPositive associationHIV outcomesInclusion criteriaPatient careLanguage articlesOutcomesLongitudinal studyRelevant databasesAssociationSystematic literature reviewNegative associationReviewLiterature reviewHIVPatientsStudyCareEfavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes
Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JAC, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine 2016, 95: e5133. PMID: 27741139, PMCID: PMC5072966, DOI: 10.1097/md.0000000000005133.Peer-Reviewed Original ResearchConceptsCD4 cell countEfavirenz regimenVirologic failureVirologic outcomesSurvival differencesNucleoside reverse transcriptase inhibitor (NRTI) backboneCell countReverse transcriptase inhibitor backboneAtazanavir-containing regimensAIDS-free survivalHuman immunodeficiency virusImmune deficiency syndromeHIV-CAUSAL CollaborationAtazanavir regimenHazard ratioClinical outcomesImmunodeficiency virusProspective studyDeficiency syndromeMean changeRegimensEfavirenzTime-varying covariatesInhibitor backboneRegimenWhen to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries
Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 72: 214-221. PMID: 26895294, PMCID: PMC4866894, DOI: 10.1097/qai.0000000000000956.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsAntiretroviral therapyCell countAIDS-defining illnessAntiretroviral-naive individualsAIDS Research NetworkMortality hazard ratioHIV-positive personsIntegrated Clinical SystemsHIV-CAUSAL CollaborationVirologic outcomesHIV RNAVirologic failureHazard ratioClinical outcomesProspective studyRisk ratioHigh-income countriesEligible individualsMonths strategyMonthsIllnessDeathTherapyThe Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality
Gaither JR, Goulet JL, Becker WC, Crystal S, Edelman EJ, Gordon K, Kerns RD, Rimland D, Skanderson M, Justice AC, Fiellin DA. The Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality. Journal Of General Internal Medicine 2016, 31: 492-501. PMID: 26847447, PMCID: PMC4835362, DOI: 10.1007/s11606-015-3571-4.Peer-Reviewed Original ResearchConceptsSubstance use disordersGuideline-concordant careCause mortalityOpioid therapyLong-term opioid therapyUntreated substance use disordersCurrent substance use disorderTerm opioid therapyTime-updated covariatesPrimary care visitsImportant clinical outcomesMulti-modal treatmentUrine drug testingUninfected patientsUntreated patientsCare visitsChronic painClinical outcomesCox regressionDecreased riskHigh comorbidityMortality burdenRehabilitative therapySUD treatmentHigh risk
2015
Comparing clinical outcomes in HIV‐infected and uninfected older men hospitalized with community‐acquired pneumonia
Barakat LA, Juthani-Mehta M, Allore H, Trentalange M, Tate J, Rimland D, Pisani M, Akgün KM, Goetz MB, Butt AA, Rodriguez-Barradas M, Duggal M, Crothers K, Justice AC, Quagliarello VJ. Comparing clinical outcomes in HIV‐infected and uninfected older men hospitalized with community‐acquired pneumonia. HIV Medicine 2015, 16: 421-430. PMID: 25959543, PMCID: PMC5015437, DOI: 10.1111/hiv.12244.Peer-Reviewed Original ResearchConceptsCommunity-acquired pneumoniaVeterans Aging Cohort StudyVACS IndexCAP outcomesAntiretroviral therapyOlder adultsHigher VACS indexDays of dischargeAging Cohort StudyUninfected participantsCohort studyMean LOSHIV infectionLonger LOSClinical outcomesUnadjusted analysesUninfected groupMultivariable modelEligibility criteriaHIVMale veteransMortality rateART useMortalityOutcomesBoosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries
Cain L, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins J, Sterne J, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende M, Abgrall S, Costagliola D, Hernán M. Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases 2015, 60: 1262-1268. PMID: 25567330, PMCID: PMC4447777, DOI: 10.1093/cid/ciu1167.Peer-Reviewed Original ResearchConceptsAtazanavir regimenVirologic failureProspective studyNucleoside reverse transcriptase inhibitor (NRTI) backboneFirst-line antiretroviral regimensReverse transcriptase inhibitor backboneAIDS-free individualsTreat hazard ratiosCD4 cell countCurrent clinical guidelinesHuman immunodeficiency virusRandomized clinical trialsAdjusted intentionAntiretroviral regimensAtazanavir groupBoosted atazanavirContaining RegimensVirologic outcomesCD4 countNRTI backboneHazard ratioClinical outcomesImmunodeficiency virusClinical guidelinesClinical trials
2012
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study
Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS 2012, 26: 1691-1705. PMID: 22546987, PMCID: PMC3647467, DOI: 10.1097/qad.0b013e328354f497.Peer-Reviewed Original ResearchConceptsAIDS-free individualsCD4 cell countEfavirenz regimensVirologic failureVirologic outcomesCell countMore nucleoside reverseNevirapine-containing regimensTreat hazard ratiosTypes of regimensProspective observational studyHIV-CAUSAL CollaborationEffect of efavirenzEfavirenz regimenNevirapine regimenNevirapine regimensHazard ratioNucleoside reverseClinical outcomesProspective studyInverse probability weightingLower incidenceObservational studyRegimensLower mortality
2010
Patient and Provider-Reported Symptoms in the Post-cART Era
Edelman EJ, Gordon K, Justice AC. Patient and Provider-Reported Symptoms in the Post-cART Era. AIDS And Behavior 2010, 15: 853-861. PMID: 20490910, PMCID: PMC3118476, DOI: 10.1007/s10461-010-9706-z.Peer-Reviewed Original ResearchConceptsPatient-reported symptomsPost-cART eraClinical outcomesVeterans Aging Cohort StudyAging Cohort StudyHealth-related qualityBaseline survey dataCohort studySymptoms patientsHigh burdenSecondary analysisSymptomsPatientsPrimary providersGold standardKappa scoresHospitalizationRegression analysisMortalityOutcomesProvidersPoor agreementHRQoLHIVPrevalence
2008
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Mugavero M, May M, Harris R, Saag M, Costagliola D, Egger M, Phillips A, Günthard H, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill M, Justice A, D'Arminio Monforte A, Lampe F, Miró J, Staszewski S, Sterne J. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS 2008, 22: 2481-2492. PMID: 19005271, PMCID: PMC2793403, DOI: 10.1097/qad.0b013e328318f130.Peer-Reviewed Original ResearchConceptsAntiretroviral-naïve patientsAntiretroviral therapyLopinavir/ritonavirVirologic failureClinical eventsThird drugART initiationCohort studyAntiretroviral Therapy Cohort CollaborationNaïve HIV-positive patientsHIV-positive patientsObservational cohort studyHIV Cohort StudyART regimenCohort CollaborationNaïve patientsClinical outcomesResidual confoundingClinical practicePatientsInhibitor backboneAbacavirNevirapineTherapyDrugs
2004
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. The Lancet 2004, 364: 51-62. PMID: 15234856, DOI: 10.1016/s0140-6736(04)16589-6.Peer-Reviewed Original ResearchConceptsProportional hazards modelVirological failureCD4 cell count slopesHIV-1 RNA concentrationsCox proportional hazards modelCD4 cell countPredictors of deathAntiretroviral therapyHIV cohortDual therapyClinical outcomesViral loadHIV replicationDrug classesTreatment strategiesTreatment informationPatientsDemographic characteristicsRNA concentrationRegression analysisTherapyFailureCohort